eligibility_summary
Eligibility: MM (IMWG) with measurable, progressive disease, ECOG 0-1, life expectancy >=12 wks, prior AEs <=G1, adequate organ function. Excludes: pregnancy/breastfeeding, plasma cell leukemia, amyloidosis/MDS, recent mAb/ADC (<4 wks/5 half-lives) or other therapy (<14 d), solid organ transplant, active autoimmune disease, chronic EBV, HBV/HCV, HIV, live vaccine <1 mo or not fully COVID-vaccinated, carfilzomib refractory/toxicity, liver cirrhosis, SCT-eligible.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06055075 (Phase Ib/II, r/r multiple myeloma) tests forimtamig alone or with carfilzomib or daratumumab. Forimtamig: subcutaneous bispecific T‑cell–engaging antibody (immunotherapy) that binds GPRC5D on myeloma cells and CD3 on T cells, activating T‑cell cytotoxicity against GPRC5D+ plasma cells. Carfilzomib: intravenous irreversible proteasome inhibitor (epoxyketone) blocking the 20S proteasome’s chymotrypsin‑like activity, triggering apoptotic stress in myeloma cells. Daratumumab: subcutaneous anti‑CD38 IgG1 monoclonal antibody inducing direct apoptosis plus CDC, ADCC, and ADCP, and depleting CD38+ immunosuppressive cells. Targets/pathways: GPRC5D, CD3/T‑cell activation, proteasome/ubiquitin pathway, CD38 on plasma cells.